RARE

APLS BBIO Biotechnology BMRN CRSP NTLA RARE RGNX Uncategorized

Rare disease pharmas could benefit from FDA guidance to accelerate development

Feb 23, 2026

Biotechnology RARE Uncategorized

Ultragenyx granted FDA priority review for rare metabolic disorder gene therapy

Feb 23, 2026

Biotechnology KYKOF KYKOY RARE Uncategorized

Ultragenyx falls as guidance trails consensus amid job cuts

Feb 13, 2026

Biotechnology RARE Uncategorized

Ultragenyx Pharmaceutical GAAP EPS of -$1.29 misses by $0.16, revenue of $207M beats by $5.14M

Feb 12, 2026

ultragenyx-releases-new-data-on-sanfilippo-syndrome-gene-therapy

Biotechnology RARE Uncategorized

Ultragenyx releases new data on Sanfilippo syndrome gene therapy

Feb 3, 2026

Ultragenyx Pharmaceutical (RARE) said that new long-term data for its AAV9 gene therapy for Sanfilippo...

ultragenyx-completes-rolling-fda-submission-for-us-approval-of-gene-therapy

Biotechnology RARE Uncategorized

Ultragenyx completes rolling FDA submission for US approval of gene therapy

Dec 31, 2025

Comments Ultragenyx Pharmaceutical (RARE) has completed the rolling submission of its U.S. marketing application for...

Biotechnology MREO RARE Uncategorized

Ultragenyx recovers some losses as Jefferies sees potential 2026 rebound

Dec 30, 2025

Biotechnology DBRG RARE Uncategorized

Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical

Dec 29, 2025

Biotechnology MREO RARE Uncategorized

Ultragenyx plummets as late-stage studies of asset for genetic bone disorder fails

Dec 29, 2025